KRAS-mutant colorectal cancer
GPTKB entity
Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:colorectal_cancer_subtype
|
| gptkbp:associatedWith |
precision medicine
metastatic colorectal cancer tumor progression poor prognosis RAS pathway activation reduced response to cetuximab reduced response to panitumumab |
| gptkbp:detects |
molecular testing
|
| gptkbp:has_genetic_alteration |
gptkb:KRAS_mutation
|
| gptkbp:has_primary_site |
colon
rectum |
| gptkbp:is_resistant_to |
anti-EGFR therapy
|
| gptkbp:is_treated_with |
gptkb:targeted_therapy
chemotherapy |
| gptkbp:studiedBy |
oncology research
|
| gptkbp:bfsParent |
gptkb:EGFR_inhibitors_(in_colorectal_cancer)
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
KRAS-mutant colorectal cancer
|